Baird raised the firm’s price target on Astrana Health (ASTH) to $45 from $40 and keeps an Outperform rating on the shares. The firm updated its model following results as the story is strengthening and where MA margin upside is taking shape.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASTH:
- Astrana Health reports Q1 adjusted EPS 74c, consensus 65c
- Astrana Health sees Q2 revenue $965M-$1B, consensus $973.68M
- Astrana Health sees FY26 revenue $3.8B-$4.1B, consensus $3.99B
- Astrana Health Posts Strong Q1 Growth, Reaffirms 2026 Outlook
- Astrana Health price target raised to $40 from $37 at Baird